Octagon Capital Advisors’s Cidara Therapeutics CDTX Stock Holding History

Octagon Capital Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$22.1M	–	30
2025 Q4	$22.1M	Hold	100,000	–	–	2.68%	14
2025 Q3	$9.58M	Buy	+100,000	New	+$6.38M	1.45%	21

Octagon Capital Advisors's CDTX Position: Q1 2026 in Review

Octagon Capital Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 100,000 shares — an estimated $22.1M sold.

Octagon Capital Advisors first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $22.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Octagon Capital Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Octagon Capital Advisors sold 100,000 Cidara Therapeutics shares in Q1 2026, an estimated $22.1M.
Octagon Capital Advisors first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
Octagon Capital Advisors's Cidara Therapeutics position peaked at $22.1M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.